University of PittsburghUniversity of Pittsburgh
Technologies
TechnologiesProductsCollectionsChat with AI
Sign in
University of Pittsburgh

Glutaminase Inhibitors

OverviewRequest InfoMore Like ThisProducts

Technology Type

Therapeutic Modality

Technology Subtype

Small Molecule

Therapeutic Areas

Oncology

Therapeutic Indications

Ductal carcinoma (Breast cancer)

Lead Inventor

Lee McDermott

Department

Pharm-Pharmaceutical Science

All Innovators

Prema Chandrasekhar IyerLee Apostle McDermott

Technology Readiness Level

3. Initial proof of concept, in-vivo

Date Submitted

Apr 29, 2014

Reference Number

03304

Kidney-type glutaminase is a key player in the altered metabolic pathways of tumor cells. Upregulation of its GAC isoform and high utilization of its substrate glutamine are seen in a number of cancer cell lines. High glutamine utilization and dependence by cancer cells has been well-documented and is referred to as “glutamine addiction.” Inhibition of glutaminase through antisense, siRNA, and small molecule inhibitors has been shown to lead to a reduction in tumor cell proliferation as well as tumor size reduction in mice and is a promising approach to fighting cancer.

Description

A novel series of small molecule inhibitors of kidney-type glutaminase was designed and synthesized. The series includes derivatives with excellent drug-like properties and potency when compared to leading literature compounds. Outstanding in vivo tumor growth inhibition has been demonstrated by treating mice implanted with patient-derived triple negative breast cancer tumor grafts with low doses of a compound from our series in combination with bevacizumab. These compounds starve cancer cells of the glutamine they need to survive and proliferate, and offer a promising new tool in the fight against cancer.

Applications

· Inhibition/treatment of cancers dependent on glutamine
· Inhibition/treatment of triple negative breast cancer
· Combination regiments with other chemotherapeutics

Advantages

· Ease of synthesis that allows for quick expansion of the pool of available compounds and further optimization
· Excellent drug-like properties, metabolic stability, and potency.

Invention Readiness

In vivo data

IP Status

https://patents.google.com/patent/US10245254B2

Related Publication(s)

McDermott, L. A., Iyer, P., Vernetti, L., Rimer, S., Sun, J., Boby, M., Yang, T., Fioravanti, M., O’Neill, J., Wang, L., Drakes, D., Katt, W., Huang, Q., & Cerione, R. (2016). Design and evaluation of novel glutaminase inhibitors. Bioorganic & Medicinal Chemistry, 24(8), 1819–1839. https://doi.org/10.1016/j.bmc.2016.03.009

Huang, Q., Stalnecker, C., Zhang, C., McDermott, L. A., Iyer, P., O’Neill, J., Reimer, S., Cerione, R. A., & Katt, W. P. (2018). Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. Journal of Biological Chemistry, 293(10), 3535–3545. https://doi.org/10.1074/jbc.m117.810101

McDermott, L., Koes, D., Mohammed, S., Iyer, P., Boby, M., Balasubramanian, V., Geedy, M., Katt, W., & Cerione, R. (2019). GAC inhibitors with a 4-hydroxypiperidine spacer: Requirements for potency. Bioorganic & Medicinal Chemistry Letters, 29(19), 126632. https://doi.org/10.1016/j.bmcl.2019.126632

Discover More with AI